LPL Financial LLC Has $3.79 Million Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

LPL Financial LLC lifted its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 19.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 413,235 shares of the medical technology company's stock after acquiring an additional 68,516 shares during the period. LPL Financial LLC owned about 0.29% of Alphatec worth $3,793,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new position in shares of Alphatec in the fourth quarter worth $228,000. American Century Companies Inc. boosted its stake in Alphatec by 36.5% during the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock valued at $45,800,000 after purchasing an additional 1,334,780 shares during the period. Semanteon Capital Management LP bought a new position in Alphatec in the fourth quarter worth $302,000. Intech Investment Management LLC lifted its holdings in shares of Alphatec by 14.7% during the 4th quarter. Intech Investment Management LLC now owns 38,904 shares of the medical technology company's stock worth $357,000 after acquiring an additional 4,985 shares during the period. Finally, First Eagle Investment Management LLC boosted its holdings in Alphatec by 36.6% during the fourth quarter. First Eagle Investment Management LLC now owns 658,437 shares of the medical technology company's stock valued at $6,044,000 after purchasing an additional 176,402 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company's stock.

Insiders Place Their Bets

In other Alphatec news, CEO Patrick Miles sold 12,691 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the sale, the chief executive officer now directly owns 5,857,603 shares of the company's stock, valued at $62,324,895.92. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Sponsel sold 12,946 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $10.73, for a total transaction of $138,910.58. Following the sale, the executive vice president now directly owns 722,128 shares in the company, valued at $7,748,433.44. This trade represents a 1.76 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 278,800 shares of company stock valued at $3,201,469. 22.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Piper Sandler increased their target price on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Barclays upped their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Alphatec in a report on Monday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Alphatec currently has an average rating of "Moderate Buy" and a consensus target price of $17.67.

Alphatec Price Performance

Alphatec stock traded up $0.09 during trading hours on Wednesday, reaching $10.00. 131,523 shares of the stock were exchanged, compared to its average volume of 2,026,897. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $13.79. The company has a market cap of $1.44 billion, a P/E ratio of -7.81 and a beta of 1.20. The stock has a 50 day moving average of $10.41 and a two-hundred day moving average of $9.38.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. Equities analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.